In recent years numerous life-saving treatment options have been developed for the therapy of breast cancer. Today there is a wide selection of treatments available to fight each individual breast cancer type. For a personalized treatment recommendation different approaches are selected and combined based on a sound diagnosis.
Clinical parameters guide the oncologist in assessing the suitable intervention e.g.:
In order to optimize the outcome the treatment regimen is typically complemented by a systemic therapy like:
Based on the identified molecular subtype the 13th St Gallen International Breast Cancer Conference (2013) Expert Panel has established clear recommendations for the choice of most effective systemic treatments.
|Subtype||Systemic Therapy||Benefits of MammaTyper®|
|Luminal A-like||Endocrine therapy||Based on accurate measurement MammaTyper® supports differentiation of low risk
Luminal A-like from high risk Luminal B-like by precise and reproducible MKI67 determination
|Luminal B-like (HER2 negative)||Endocrine therapy
|Accurate determination of hormone receptor > endocrine responder or non –responder
Precise differentiation of low risk Luminal A-like from high risk Luminal B-like by accurate and reproducible MKI67 determination by MammaTyper®
|Luminal B-like (HER2 positive)||Endocrine therapy
|Accurate determination of hormone receptor expression by MammaTyper® > endocrine responder or non –responder
Accurate determination of ERBB2 expression by MammaTyper®
|HER2 positive (non-luminal)||Anti-HER2||Accurate determination of ERBB2 expression by MammaTyper®|
|Triple negative (ductal)||Cytotoxics||Accurate determination of ERBB2, ESR1, PGR expression negativity by MammaTyper®|